Cannabis has a more complex relationship with epilepsy than with almost any other condition. CBD is now an FDA-approved seizure treatment — the active ingredient in Epidiolex, the first plant-derived cannabis medicine ever approved in the United States. At the same time, high-THC cannabis can be proconvulsant in some people, meaning it can trigger or worsen seizures. Understanding which compounds help, which can harm, and at what doses is essential before any person with epilepsy considers cannabis. This page covers the science, the evidence, the risks, and the path to accessing medical cannabis legally if it is appropriate for you.
Get your medical marijuana card
Can marijuana cause seizures — and can it also prevent them?
Both are true, depending on which compound you are talking about and at what dose. This is not a contradiction — it reflects the fact that cannabis contains dozens of cannabinoids with different and sometimes opposing effects on brain excitability.
How THC can cause or worsen seizures
THC (delta-9-tetrahydrocannabinol) acts as a partial agonist at CB1 receptors, which are distributed throughout the brain including in regions that regulate seizure threshold. Its effects on seizure activity are dose-dependent and inconsistent:
- A 2022 scoping review of 13 human studies found that ten showed a higher-than-expected incidence of seizures in populations exposed to cannabis products, identifying THC as the likely causative compound[1]
- Case reports and emergency room data consistently link high-potency THC — particularly synthetic cannabinoids and very high-THC flower — with new-onset seizures, including in people with no prior epilepsy history
- A 2025 case series in Epilepsy & Behavior Reports documented two patients with focal epilepsy whose seizure control deteriorated with chronic cannabis use, with breakthrough seizures temporally linked to cannabis use[2]
- Synthetic cannabinoid receptor agonists (SCRAs — “spice” or “K2”) carry significantly higher proconvulsant risk than plant-derived cannabis and should be avoided entirely by anyone with epilepsy
⚠ Who is most at risk of THC-triggered seizures
People with pre-existing epilepsy, children and adolescents (whose developing brains are more sensitive to THC), people using high-potency products (above ~15% THC flower, or concentrates), and people using synthetic cannabinoids are at the highest risk. If you have epilepsy and are considering cannabis, only high-CBD, low-THC products should be considered — and only under the supervision of your neurologist.
How CBD prevents seizures
CBD’s anticonvulsant mechanisms are well established and distinct from THC:
- VGSC inhibition — CBD blocks voltage-gated sodium channels (Nav1.1, Nav1.6), reducing the abnormal electrical firing that causes seizures. This is the same target as some existing antiseizure medications (e.g. carbamazepine, lamotrigine)
- GPR55 antagonism — CBD blocks GPR55, a receptor that when activated promotes neuronal excitability. Blocking it has anticonvulsant effects
- TRPV1 modulation — CBD desensitises TRPV1 channels, reducing the calcium influx that contributes to seizure generation
- Adenosine uptake inhibition — by increasing adenosine levels, CBD produces anti-inflammatory and seizure-suppressive effects in the brain
- GABAergic enhancement — CBD potentiates GABA-A receptor activity, promoting inhibitory neurotransmission that counteracts the excitatory drive of seizures
Critically, these mechanisms do not require CB1 receptor activation — meaning CBD’s anticonvulsant effects operate largely independently of THC and are not accompanied by intoxication.
What about other cannabinoids?
Beyond CBD and THC, several minor cannabinoids show anticonvulsant promise:
| Cannabinoid | Evidence for seizure relevance |
|---|---|
| CBDV | Cannabidivarin — structural analogue of CBD with demonstrated anticonvulsant activity in animal models; particularly studied for Dravet syndrome and Rett syndrome |
| CBDA | Cannabidiolic acid (raw/unheated CBD) — preclinical evidence suggests greater bioavailability and anticonvulsant potency than CBD at lower doses in some models |
| THCA | Tetrahydrocannabinolic acid (raw/unheated THC) — unlike THC itself, THCA does not readily cross the blood-brain barrier and has shown anticonvulsant properties without psychoactivity in preclinical research |
| CBC | Cannabichromene — limited human evidence, but animal studies suggest TRP channel modulation with some anticonvulsant effects |
Get your medical marijuana card
Epidiolex and the clinical evidence for CBD in epilepsy
CBD in epilepsy has moved beyond anecdote — it now has a stronger evidence base than cannabis for most other conditions, precisely because it could be studied as a pharmaceutical product (Epidiolex) rather than as whole-plant cannabis. This distinction matters enormously for quality of evidence.
FDA approval: what Epidiolex is approved for
Epidiolex (GW Pharmaceuticals / Jazz Pharmaceuticals) is pharmaceutical-grade, plant-derived CBD oral solution. It is FDA-approved in the US for:
- Dravet syndrome (DS) — a severe childhood-onset epilepsy caused by SCN1A gene mutations, characterised by prolonged, frequent seizures that are resistant to most antiseizure medications
- Lennox-Gastaut syndrome (LGS) — a severe childhood epilepsy involving multiple seizure types (especially drop seizures) and developmental delay; also typically resistant to conventional treatment
- Tuberous sclerosis complex (TSC) — a genetic disorder causing benign tumours throughout the body, including in the brain, with associated seizures that can be severe and drug-resistant
Epidiolex is approved for patients aged 1 year and older. It is available by prescription in all 50 states regardless of state cannabis laws — because as an FDA-approved medication, it is classified as a Schedule V controlled substance, not Schedule I.
Key trial results
| Condition / Trial | Key result |
|---|---|
| Dravet syndrome (Devinsky et al., NEJM 2017)[3] | Median monthly convulsive seizure frequency reduced by 38.9% vs 13.3% placebo. 5% of CBD patients became seizure-free vs 0% placebo |
| Lennox-Gastaut syndrome (Thiele et al., NEJM 2018)[4] | Median drop seizure reduction: 43.9% (CBD 20 mg/kg/day) vs 21.8% (placebo). Significant difference at both doses tested |
| Tuberous sclerosis complex (Thiele et al., Lancet Neurology 2021) | TSC-associated seizures reduced by 48.6% (CBD 25 mg/kg/day) vs 26.5% (placebo). Clinically meaningful response in a high proportion of patients |
| Drug-resistant epilepsy (open-label) (Devinsky et al., Lancet Neurology 2016)[5] | 214 patients with treatment-resistant epilepsy across multiple epilepsy types; 36.5% median reduction in seizure frequency at 12 weeks. 2 patients became seizure-free |
Beyond Dravet and LGS: expanding evidence
A 2025 review in Frontiers in Pharmacology noted that evidence for CBD’s anticonvulsant benefit is accumulating beyond the three approved indications, with studies showing meaningful seizure reduction in focal epilepsies, generalised epilepsies, and other rare epileptic syndromes in both children and adults.[6] Real-world Epidiolex use studies also show good long-term tolerability and therapy retention in drug-resistant epilepsy not limited to the approved syndromes.
⚠ Epidiolex vs. dispensary CBD products: a critical difference
Epidiolex is a pharmaceutical-grade product with confirmed purity, standardised dosing, and the full FDA approval process behind it. Dispensary or over-the-counter CBD products vary enormously in actual cannabinoid content, may contain solvents or heavy metals (especially hemp-derived extracts), and have not been tested in clinical trials. If you have epilepsy and are considering CBD, discuss Epidiolex with your neurologist before trying unregulated products. If Epidiolex is not accessible or affordable, a Leafwell physician can help you identify tested, high-quality CBD products available through your state’s medical cannabis program.
How to use cannabis for epilepsy: products, ratios, and dosing
Epilepsy is unlike most other medical cannabis conditions in that the choice of product is not primarily about symptom relief preference — it is a safety question. The wrong product (high THC) can worsen your condition.
Recommended CBD:THC ratios for epilepsy
For drug-resistant epilepsy (adults)
A high-CBD, very low-THC ratio — 20:1 or 25:1 CBD:THC — is the standard starting point, mirroring the cannabinoid profile of Epidiolex (which contains only trace THC from plant extraction). These products provide anticonvulsant CBD while keeping THC below a threshold that could compromise seizure threshold. In states with access to pharmaceutical-grade Epidiolex, that is the first choice; dispensary high-CBD products are the alternative where cost or access is a barrier.
For co-occurring symptoms (pain, sleep, anxiety alongside epilepsy)
Some epilepsy patients need relief from symptoms — chronic pain, sleep disruption, or anxiety — that a higher-THC product might address. If your epilepsy is well-controlled and your neurologist approves, a cautious trial of a 1:1 or 2:1 CBD:THC product at low doses (2.5 mg THC maximum starting dose) may be considered. This should only be done with physician oversight and careful monitoring of seizure frequency. Never increase THC dose without first confirming seizure control has not changed.
Delivery methods for epilepsy
| Method | Notes for epilepsy patients |
|---|---|
| Oral solution / tincture | Preferred delivery route — mirrors Epidiolex’s oral solution format. Predictable dosing, consistent absorption, easy to titrate. Sublingual dosing (under tongue) speeds onset to 15–30 min |
| Capsule / softgel | Good for sustained daily dosing; slower onset (30–90 min); suitable for maintenance therapy when seizure control is established |
| Vaporised flower / concentrate | Generally not recommended for epilepsy — THC content in inhalable products is difficult to control precisely, and many high-CBD flower strains still contain 2–5% THC. Dosing unpredictability increases risk |
| Edible | Highly variable absorption; onset 30–120 min; difficult to titrate. Use only for CBD-dominant products with confirmed dosing. Not suitable for acute seizure management |
Dosing guidance
Epidiolex trials used doses of 10–20 mg/kg/day, divided into two daily doses. For dispensary CBD products, dosing guidance is less standardised:
- Starting dose: 2.5–5 mg CBD twice daily for adults; increase by 2.5 mg every 1–2 weeks based on response and tolerability
- For Dravet syndrome, doses of 10 mg/kg/day (split twice daily) are commonly used in clinical settings
- Children’s dosing must be managed by a paediatric neurologist — do not attempt to translate adult dosing to children
- Keep a detailed seizure diary throughout titration — frequency, duration, type, and severity — so your physician can assess response objectively
⚠ Drug interactions: CBD and antiseizure medications
CBD inhibits CYP3A4 and CYP2C19 liver enzymes, which metabolise many antiseizure medications. The most clinically significant interactions:
Clobazam (Onfi) — CBD dramatically increases levels of N-desmethylclobazam, the active metabolite of clobazam. This can enhance both the therapeutic effect and side effects (sedation, ataxia). Most neurologists reduce clobazam dose when adding CBD.
Valproate (Depakote) — CBD combined with valproate may increase liver enzyme elevation; liver function must be monitored closely.
Stiripentol — used in Dravet syndrome; combination with CBD requires careful monitoring.
Other CYP-metabolised ASMs — carbamazepine, phenytoin, phenobarbital, and topiramate may all be affected. Always disclose CBD use to the prescribing neurologist before starting.
Does epilepsy qualify for a medical marijuana card?
Yes — epilepsy and seizure disorders are among the most universally recognised qualifying conditions in US medical cannabis programs. Every state with a medical cannabis program lists epilepsy, seizure disorders, or intractable epilepsy as a qualifying condition — making it one of only a handful of conditions with 100% qualifying status across all medical states.
| Condition | Qualifying status |
|---|---|
| Epilepsy / seizure disorders | Qualifying condition in all 38+ US medical cannabis states |
| Intractable / drug-resistant epilepsy | Specifically listed in several states; particularly relevant for Dravet, LGS, and TSC patients |
| Dravet syndrome | Covered under epilepsy/seizure disorder in all states; Epidiolex also available as prescription without a medical card |
| Tuberous sclerosis complex | Qualifying in most states; seizures are primary qualifying symptom |
| Chronic pain | Qualifies independently in every medical state; relevant if pain accompanies neurological condition |
A note on Texas and restrictive-access states
Texas operates a Compassionate Use Program (CUP) that is more restrictive than most states — it caps THC at 1% and limits dispensary access. However, epilepsy is an explicitly listed qualifying condition in Texas (added in 2015 as one of the original qualifying conditions). Products available through the Texas CUP are inherently high-CBD, low-THC, which is precisely the profile recommended for epilepsy. Leafwell physicians are authorised to provide certifications in Texas.
Epidiolex vs. a medical cannabis card — which do you need?
For patients with Dravet syndrome, LGS, or TSC, Epidiolex is the first conversation to have with your neurologist — it is covered by most insurance plans, including Medicaid in many states, and does not require a state medical cannabis card. A medical cannabis card becomes relevant when:
- Epidiolex has not provided adequate seizure control and the patient wants to explore whole-plant products
- The patient has a different epilepsy type not covered by Epidiolex’s approved indications
- Cost or insurance coverage makes Epidiolex inaccessible (dispensary CBD products may be more affordable)
- The patient also has co-occurring conditions (pain, sleep, anxiety) for which medical cannabis may provide additional benefit
Get your medical marijuana card
Understanding epilepsy and seizure disorders
Epilepsy is a chronic neurological condition defined by recurrent, unprovoked seizures — brief episodes of abnormal, excessive electrical activity in the brain. Around 3.4 million Americans live with epilepsy (approximately 1.2% of the US population), including 2.9 million adults and 456,000 children. About one in three people with epilepsy have drug-resistant or intractable epilepsy, meaning seizures are not adequately controlled by two or more antiseizure medications — this population is the primary target for cannabis-based treatment.
Types of seizures and epilepsy
- Focal (partial) seizures — start in one area of the brain; may involve altered consciousness, motor symptoms, or sensory experiences. Can spread to become generalised
- Generalised tonic-clonic seizures — the “grand mal” seizure; involves the entire brain, causing loss of consciousness and full-body convulsions
- Absence seizures — brief lapses in awareness (staring spells), most common in children; can be mistaken for daydreaming
- Myoclonic seizures — sudden muscle jerks, typically in the arms or upper body; often occur in the morning in people with juvenile myoclonic epilepsy
- Atonic (drop) seizures — sudden loss of muscle tone causing falls; a defining feature of Lennox-Gastaut syndrome
- Dravet syndrome — severe childhood-onset epilepsy with SCN1A mutations; characterised by prolonged febrile seizures and multiple seizure types; notoriously drug-resistant and one of the key conditions for CBD treatment
- Lennox-Gastaut syndrome (LGS) — childhood-onset with multiple seizure types, cognitive impairment, and characteristic EEG pattern; highly resistant to medication
- Tuberous sclerosis complex (TSC) — genetic condition causing benign tumours throughout the body including the brain; 90% of TSC patients develop epilepsy, often severe
Standard treatments
- Antiseizure medications (ASMs) — over 30 approved ASMs in the US; first-line agents include levetiracetam, lamotrigine, valproate, carbamazepine, and oxcarbazepine. About 65–70% of patients achieve seizure control with ASMs
- Ketogenic diet — high-fat, low-carbohydrate diet; shown to reduce seizures in drug-resistant epilepsy, particularly in children. Requires close medical supervision
- Vagus nerve stimulation (VNS) — implanted device that delivers electrical impulses to the vagus nerve to reduce seizure frequency; used in drug-resistant epilepsy
- Responsive neurostimulation (RNS) — implanted brain device that detects and responds to abnormal electrical activity in real time; for focal drug-resistant epilepsy
- Epilepsy surgery — resection of the seizure focus; potentially curative for suitable focal epilepsy candidates; not appropriate for generalised epilepsy
- Epidiolex (CBD) — FDA-approved for Dravet, LGS, and TSC; first-line consideration in drug-resistant forms of these syndromes
- Medical cannabis (whole-plant) — for patients with drug-resistant epilepsy of other types, or where Epidiolex has been insufficient or inaccessible
